Short answer
BridgeBio Pharma, Inc. (BBIO) filed an 8-K current report with the SEC on August 17, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.2). KKR Genetic Disorder selling 5,000,000 BridgeBio shares at $78.00 each.
BridgeBio Pharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- KKR Genetic Disorder selling 5,000,000 BridgeBio shares at $78.00 each
- Gross offering value approximately $390 million, accruing to the selling stockholder
- BridgeBio receives no proceeds, limiting direct balance-sheet benefit from the transaction
- Closing expected August 17, 2026, increasing near-term public share supply
- Offering underwritten by William Blair, Goldman Sachs, and KKR Capital Markets-vesm
Item 8.01 · Other Events
- BridgeBio launched a securities offering on August 13, 2026
- Offering pricing announced August 14, 2026
- Investor-relevant terms and potential dilution appear in Exhibits 99.1 and 99.2
Item EX-99.1 · Exhibit EX-99.2
- KKR Genetic Disorder L.P. launched a secondary offering of 5,000,000 BBIO shares
- BridgeBio is not selling shares and will receive no proceeds, making this non-dilutive to the company
- Potential increase in public float, with possible near-term selling pressure from the large shareholder exit
- Offering completion, size, pricing, and terms remain subject to market conditions
- Final terms expected in a prospectus supplement filed with the SEC
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BridgeBio Pharma, Inc. 8-K filings
Get the next BBIO 8-K as it lands
Follow BBIO for push alerts, or ask the research agent what this filing means.